Efficacy of concomitant administration of nebulized lasix and salbutamol on spirometric indices of asthmatic patients

Assessment of the efficacy of concomitant administration of nebulized lasix and salbutamol on spirometric indices of patients with persistent asthma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201104136187N1

Enrollment

Registered

2011-07-10

Start date

2011-04-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Asthma, unspecified

Interventions

Intervention 1: 2.5 mg salbuthamol +10 mg furosemide is nebulized in intervention group for 30 minute. Intervention 2: 2.5 mg salbuthamol is nebulized in control group for 30 minute.

Treatment - Drugs

2.5 mg salbuthamol +10 mg furosemide is nebulized in intervention group for 30 minute

2.5 mg salbuthamol is nebulized in control group for 30 minute

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Asthma diagnosis based on signs of cough, sputum, intermittent and variable dyspnea, wheezing, and chest tightness for at least 6 months; diagnosis of asthma has been confirmed previously by specialists using following criteria: decline of FEV1/FVC, PEF, FEV1 and increasing FEV1>12% and >200ml after 15 min receiving short acting beta2 agonist or consuming corticosteroids orally for 2-4 weeks (prednisolone 30-40 mg daily). Among asthmatic patients only those who have persistent asthma (i.e. at least more than 2 nocturnal attacks per month and/or at least more than 2 daily attacks per week) are eligible cases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FEV1(forced expiratory volume in 1 second) improvment. Timepoint: 30 minute after nebulization. Method of measurement: Spirometry.;FVC(forced expiratory vital capacity) improvment. Timepoint: 30 minute after nebulization. Method of measurement: Spirometry.;MMEF(maximum midexpiratory flow) improvment. Timepoint: 30 minute after nebulization. Method of measurement: Spirometry.;Peak expiratory flow improvment. Timepoint: 30 minute after nebulization. Method of measurement: Spirometry.	—

Measure

Time frame

FEV1(forced expiratory volume in 1 second) improvment. Timepoint: 30 minute after nebulization. Method of measurement: Spirometry.;FVC(forced expiratory vital capacity) improvment. Timepoint: 30 minute after nebulization. Method of measurement: Spirometry.;MMEF(maximum midexpiratory flow) improvment. Timepoint: 30 minute after nebulization. Method of measurement: Spirometry.;Peak expiratory flow improvment. Timepoint: 30 minute after nebulization. Method of measurement: Spirometry.

—

Secondary

Measure	Time frame
Bronchospasm. Timepoint: 30 minute after nebulization. Method of measurement: Clinical evaluation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammadali Saba

kashan university of medical sciences

saba-ma@kaums.ac.ir+98 36 1555 0026

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026